RU2016151235A - Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус - Google Patents

Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус Download PDF

Info

Publication number
RU2016151235A
RU2016151235A RU2016151235A RU2016151235A RU2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A RU 2016151235 A RU2016151235 A RU 2016151235A
Authority
RU
Russia
Prior art keywords
human
cynomolgus
antibody
monkey
specifically binds
Prior art date
Application number
RU2016151235A
Other languages
English (en)
Russian (ru)
Other versions
RU2016151235A3 (enExample
Inventor
Георг ТИФЕНТАЛЕР
Эккехард Мёсснер
Валерия ЛИФКЕ
Йозеф Платцер
Соня ОФФНЕР
Кристиане Йегер
Мирко РИТТЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2016151235A publication Critical patent/RU2016151235A/ru
Publication of RU2016151235A3 publication Critical patent/RU2016151235A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2016151235A 2014-05-28 2015-05-22 Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус RU2016151235A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (2)

Publication Number Publication Date
RU2016151235A true RU2016151235A (ru) 2018-06-28
RU2016151235A3 RU2016151235A3 (enExample) 2019-01-18

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151235A RU2016151235A (ru) 2014-05-28 2015-05-22 Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3763739A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
FI3561057T3 (fi) * 2016-12-22 2025-10-07 Daiichi Sankyo Co Ltd Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
TWI820041B (zh) * 2017-09-21 2023-11-01 中國大陸商上海藥明生物技術有限公司 新型抗CD3ε抗體
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
MX420253B (es) * 2018-05-24 2025-02-10 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
IL298444A (en) * 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
JP2023542209A (ja) * 2020-09-24 2023-10-05 モルフォシス・アーゲー ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
KR20240158351A (ko) * 2022-03-22 2024-11-04 모르포시스 아게 Cd3에 특이적인 탈면역화 항체
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
DK2155788T3 (da) * 2007-04-03 2012-10-08 Amgen Res Munich Gmbh Krydsartsspecifikke bispecifikke bindemidler
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN107827985A (zh) * 2011-05-21 2018-03-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
RU2016151235A3 (enExample) 2019-01-18
US20200299385A1 (en) 2020-09-24
US20200325224A1 (en) 2020-10-15
KR20170003591A (ko) 2017-01-09
CA2942453A1 (en) 2015-12-03
JP6738285B2 (ja) 2020-08-12
MX2016015389A (es) 2017-04-13
CN106459201A (zh) 2017-02-22
AU2015266077A1 (en) 2016-09-29
SG11201609950YA (en) 2016-12-29
IL247740A0 (en) 2016-11-30
BR112016022819A2 (pt) 2018-01-16
EP3763739A1 (en) 2021-01-13
JP2017516786A (ja) 2017-06-22
US20170233475A1 (en) 2017-08-17
EP3149041A1 (en) 2017-04-05
WO2015181098A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
RU2016151235A (ru) Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
JP2017516786A5 (enExample)
RU2020124623A (ru) Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2013538057A5 (enExample)
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
RU2016100892A (ru) Антитела против tweakr и их применение
PE20230408A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
RU2017104642A (ru) Новое антитело против tie-2 человека
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
BR112018006579A2 (pt) anticorpos anti-humanos cd19 humanizados e métodos de uso
PE20071055A1 (es) Anticuerpos anti mn
AR103713A1 (es) Anticuerpos contra tau y sus usos
JP2014526898A5 (enExample)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
WO2013064700A3 (en) Chimeric human-camel antigens and their use
RU2017105596A (ru) Антитела к церамиду
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
JP2021500916A5 (enExample)
PE20161221A1 (es) Anticuerpos de il-21
RU2010119450A (ru) Антитело против bst2
RU2019129917A (ru) Химерный антигенный рецептор

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200806